Antibodies useful in passive influenza immunization
Inventors
Kauvar, Lawrence M. • ELLSWORTH, STOTE • Usinger, William • MCCUTCHEON, KRISTA MAUREEN • PARK, MINHA
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10654915-B2
Publication Date
2020-05-19
Expiration Date
Abstract
Specific monoclonal antibodies and fragments including bispecific antibodies thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza.
Core Innovation
The disclosed invention relates to passive immunization against influenza infection using monoclonal antibodies or antigen-binding fragments that bind to Influenza A HA0 protein. The antibodies are selected from MAB383, MAB486, MAB579, MAB699, MAB700, MAB708, MAB710, MAB711, and MAB723, with MAB579, MAB699, MAB700, MAB708, MAB710, MAB711, and MAB723 further defined by heavy chain variable regions and light chain variable regions comprising specified CDR sequences.
A further aspect of the invention is a bispecific antibody configuration. In the disclosed examples of antibody formats, a bispecific antibody comprises a first antigen-binding region and a second antigen-binding region, where the first antigen-binding region comprises a MAB579 heavy chain variable region and a MAB579 light chain variable region defined by specified CDR sequences, and the second antigen-binding region comprises a MAB53 heavy chain variable region and a MAB53 light chain variable region defined by specified CDR sequences.
The problem addressed is influenza infection in a subject, for which treatment or prophylaxis is provided by administering an effective amount of a pharmaceutical composition comprising the disclosed HA0-binding monoclonal antibody or antigen-binding fragment. The methods cover treating or prophylaxis of influenza infection by administering the effective amount to the subject, including embodiments where the subject is infected with influenza and embodiments framed as protection against influenza infection.
Claims Coverage
The document contains three independent claim sets covering HA0-binding monoclonal antibodies defined by specified variable-region and CDR sequences, methods for treatment or prophylaxis by administering a pharmaceutical composition containing the selected HA0-binding antibodies, and methods for treatment or prophylaxis using a bispecific antibody architecture with defined first and second antigen-binding regions. Across the independent claims, the main inventive content is HA0 binding combined with defined CDR-sequence content for named antibodies, and for the bispecific format, a two-region MAB579/MAB53 antigen-binding arrangement.
Influenza A HA0-binding monoclonal antibodies defined by specified CDR sequences
A monoclonal antibody, or an antigen-binding fragment thereof, selected from MAB383, MAB486, MAB579, MAB699, MAB700, MAB708, MAB710, MAB711 and MAB723 and binds to Influenza A HA0 protein, wherein MAB579, MAB699, MAB700, MAB708, MAB710, MAB711 and MAB723 are defined by heavy chain variable region CDR1, CDR2, and CDR3 sequences and light chain variable region CDR1, CDR2, and CDR3 sequences.
Treatment or prophylaxis of influenza infection via administration of HA0-binding antibody pharmaceutical composition
A method for the treatment or prophylaxis of influenza infection in a subject comprising administering an effective amount of a pharmaceutical composition comprising a monoclonal antibody, or an antigen-binding fragment thereof, selected from MAB383, MAB486, MAB579, MAB699, MAB700, MAB708, MAB710, MAB711 and MAB723 and binding to Influenza A HA0 protein, wherein the MAB579, MAB699, MAB700, MAB708, MAB710, MAB711, and MAB723 embodiments are defined by specified heavy chain variable region CDR sequences and light chain variable region CDR sequences.
Bispecific antibody architecture with defined first and second antigen-binding regions
A method for the treatment or prophylaxis of influenza infection in a subject comprising administering an effective amount of a pharmaceutical composition comprising a monoclonal antibody or antigen-binding fragment thereof that binds to Influenza A HA0 protein and is a bispecific antibody which comprises a first antigen-binding region and a second antigen-binding region, wherein the first antigen-binding region comprises a MAB579 heavy chain variable region and a MAB579 light chain variable region containing specified CDR sequences, and wherein the second antigen-binding region comprises a MAB53 heavy chain variable region and a MAB53 light chain variable region containing specified CDR sequences.
Overall, the claim coverage centers on HA0-binding monoclonal antibodies defined by named antibody selection and specified heavy/light variable-region CDR sequences, and on influenza treatment or prophylaxis methods that administer these HA0-binding antibodies. In addition, the coverage includes a bispecific format with a first antigen-binding region defined by MAB579 CDR sequences and a second antigen-binding region defined by MAB53 CDR sequences.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treatment or prophylaxis of influenza infection in a subject using an effective amount of a pharmaceutical composition comprising a disclosed HA0-binding monoclonal antibody or antigen-binding fragment.
Prophylaxis or protection against influenza infection.
Treatment on a subject infected with influenza.
Interested in licensing this patent?